Article
BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.
JCO precision oncology - 1 Sept 2022
van Not Olivier J, Blokx Willeke A M, van den Eertwegh Alfons J M, de Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion, van der Veldt Astrid A M, Boers-Sonderen Marye J, Jansen Anne M L, Wouters Michel W J M, Suijkerbuijk Karijn P M
Abstract excerpt
PURPOSE: Little is known about the effect of specific gene mutations on efficacy of immune checkpoint inhibitors in patients with advanced melanoma. MATERIALS AND METHODS: All patients with advanced melanoma treated with first-line anti-PD-1 or ipilimumab-nivolumab between 2012 and 2021 in the nationwide Dutch Melanoma Treatment Registry were included in this cohort study. Objective response rate,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.